SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.

Isaac WassermanLik Hang LeeShuji OginoMichael R MarcoChao WuXi ChenJashodeep DattaEran SadotBryan C SzeglinJose G GuillemPhilip B PatyMartin R WeiserGarrett M NashLeonard B SaltzAfsar BarlasKatia Manova-TodorovaSrijaya Prakash Babu UppadaArthur E ElghouayelPeter NtiamoahJonathan N GlickmanTsuyoshi HamadaKeisuke KosumiKentaro InamuraAndrew T ChanReiko NishiharaAndrea CercekKaruna GaneshNancy E KemenyPunita DhawanRona YaegerCharles L SawyersJulio Garcia-AguilarMarios GiannakisJinru ShiaJ Joshua Smith

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Our data show SMAD4 loss correlates with worse clinical outcome, resistance to chemotherapy, and decreased immune infiltrate, supporting its use as a prognostic marker in patients with colorectal cancer.

Keyphrases

end stage renal disease
epithelial mesenchymal transition
transforming growth factor
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
big data
machine learning
patient reported outcomes
signaling pathway
free survival
chemotherapy induced